D J Angiolillo

..This study sought to determine the prognostic implications of high platelet reactivity (HPR) assessed in type 2 diabetes mellitus (T2DM) patients while in their steady-state phase of dual antiplatelet therapy...

....

..In conclusion, in patients with T2DM on maintenance aspirin and clopidogrel therapy, the adjunctive use of pioglitazone does not result in enhanced inhibition of platelet P2Y12 mediated signalling...

..Ongoing clinical studies with prasugrel will better define the safety and efficacy profiles of this agent and potentially set the basis for new indications for use...

..Elinogrel is the only selective, competitive and reversible platelet P2Y(12) inhibitor available in both intravenous (IV) and oral formulations...

..This article provides an overview on atopaxar (E5555), an orally active protease-activated receptor-1 antagonist that has recently completed Phase II clinical investigation...

..Although there was no significant pharmacodynamic interaction when transitioning to clopidogrel therapy, further studies are warranted given that enrollment in this study was limited due to premature interruption of the main trial...

..No data are available on its association with coronary artery disease (CAD)...

....

..We review the clinical features of these new platelet inhibition therapies...

..This article reviews the currently available data regarding the efficacy and safety of prasugrel...

....

..Thus PAR-1 antagonism coupled with existing dual oral antiplatelet therapy may potentially offer more comprehensive platelet inhibition without the liability of increased bleeding...

..Several novel antiplatelet medications are currently under advanced clinical testing. Results from ongoing clinical studies will determine the efficacy and safety of these novel agents compared to those currently available...

..The aim of this pilot study was to assess the functional impact of cilostazol in T2DM patients on standard aspirin and clopidogrel treatment...

..However, the antiplatelet effects achieved are nonuniform, and a considerable number of patients persist with inadequate platelet inhibition...

....

..This article reviews the current knowledge of platelet ADP P2Y(12) receptor antagonism and the projected developments in this field...

..Investigations have shown that this may be in part related to the broad range in pharmacodynamic response to clopidogrel, which includes patients with poor platelet inhibitory effects who have an increased risk of events...

..This review summarizes the current knowledge on how antiplatelet therapy affects this high-risk patient population...

..This paper reviews the impact of individual response variability to clopidogrel on clinical outcomes and current and future directions for its management...

....

..Finally, future developments in the field directed towards individualized treatment strategies and novel antiplatelet agents are examined...

..Low-dose aspirin (LDA) and nonsteroidal anti-inflammatory drugs (NSAIDs) are often used concomitantly; however, some NSAIDs may interfere with LDA antiplatelet activity...

....

..In particular, strategies to enhance platelet P2Y(12) receptor inhibition, a key factor to improve outcomes in this patient population, are reviewed...

....

..005). In conclusion, patients with ESRD have an elevated prevalence of abnormal haemostatic profiles, which may contribute to their elevated risk of bleeding and thrombotic complications...

..Despite the marked platelet inhibition, cilostazol does not alter thrombin-mediated haemostatic processes, which may explain its ischaemic benefit without the increased risk of bleeding...

..The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM...

..The objective was to evaluate the pharmacodynamic response of switching patients on maintenance phase clopidogrel therapy after an acute coronary syndrome (ACS) to prasugrel...

..7, 27.1, 19.0 (P < 0.0001), and 3.9% (P = 0.3319), respectively. The results suggest that a metabolic drug-drug interaction exists between clopidogrel and omeprazole but not between clopidogrel and pantoprazole...

..We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy...

..An overview of the basic principles of platelet biology is given and currently available antiplatelet agents, as well as those under clinical development, are reviewed...

..This article provides an overview of the pharmacologic properties and clinical development of ticagrelor...

....

..The aim of this pilot study was to assess the functional impact of a high maintenance dose in T2DM patients with suboptimal clopidogrel-induced antiplatelet effects...

..Because metabolic activity of CYP3A4 is genetically regulated, we hypothesized that genetic variations of this enzyme may contribute to clopidogrel response variability...

..In conclusion, clopidogrel withdrawal is associated with an increase in platelet and inflammatory biomarkers in diabetic patients, supporting pleiotropic effects coupled with P2Y12 receptor antagonism...

..This study sought to assess the influence of type 2 diabetes mellitus (T2DM) and the impact of hypoglycemic treatment (insulin vs. noninsulin) on platelet function profiles in patients treated with dual oral antiplatelet therapy...

..Reduced sensitivity to antiplatelet drugs may contribute to the increased atherothombotic risk in diabetic patients...

..In the present study, platelet function profiles were assessed in patients undergoing coronary stenting receiving a standard 300-mg clopidogrel loading dose with the aim to identify low clopidogrel responders...

..25) in patient response to treatment was observed in ASA-resistant and -sensitive patients. In conclusion, ASA resistance is associated with increased platelet reactivity in patients on long-term dual antiplatelet treatment...

..To assess platelet inhibitory effects, interindividual variability in platelet inhibition as well as response to a 600 mg, compared to a standard 300 mg, clopidogrel loading dose (LD) after coronary stenting..

..However, the role of gene sequence variations of the P2Y(12) receptor in patients treated with clopidogrel has not yet been assessed...

..These findings may contribute to the increased ischemic risk observed in these patients...

..The topic of stent thrombosis in the era of DES will be reviewed in this article...

..Drug-eluting stent implantation was not associated with increased risk of PP. Plaque prolapse was not associated with stent thrombosis or increased neointimal proliferation...

..We review the preclinical pharmacology and selected ongoing clinical trials of promising novel platelet inhibitor therapies...

..The aim of this study was to examine the impact of overlapping bare-metal stent (BMS) and three different formulations of drug-eluting stent (DES) on intimal hyperplasia (IH) response of patients with diabetes mellitus (DM)...

..We compared prasugrel with clopidogrel among subjects with DM in TRITON-TIMI 38...

..Drug-eluting stents (DES) almost abolish NIH. Conversely, diabetes mellitus amplifies NIH response. The association between WSS and arterial wall response following DES and BMS implantation in diabetic patients remains to be evaluated...

..This manuscript will review the state of the art on the most commonly available platelet functional tests, describing their advantages and disadvantages and exploring their applicability in clinical practice...

..Such comprehensive information would require the performance of multiple tests if other modalities were used. This article describes current applications of cMRI for evaluation of patients with CAD...

..8 +/- 16.5%; 50% of patients with graft SES had < 1% IH at 8 months. CONCLUSION: Implantation of SES in high-risk patients with recurrent bypass graft disease is feasible. SES represents a future...

..In this review, we attempted to describe the current understanding of bifurcation anatomy and corresponding PCI strategies...

..This article summarizes the current understanding of the benefits and limitations of the commonly used antiplatelet therapies...

....

....

..This article provides an overview of ADP P2Y₁₂ receptor-inhibiting strategies, including high clopidogrel dosing regimens and novel agents under advanced clinical development...

..To examine the extent of platelet inhibition by prasugrel vs. clopidogrel in a TRITON-TIMI 38 substudy...

..This article provides an overview of the current status of knowledge on platelet thrombin receptor antagonists, focusing on pharmacologic properties and clinical development...

..The aim of this review is to critically analyze the contribution of hypertriglyceridemia to the occurrence of IS...

..Black holes were also identified in a nonirradiated population, although the incidence was lower than in the post-brachytherapy patients. Bare metal stents were not associated with this phenomenon...

..This article discusses variability in individual responses to oral antiplatelet therapy and its implications for clinical outcomes...

..Recent clinical trial data analyses have led to a better understanding of the efficacy and safety of prasugrel. This article reviews the currently available data regarding the efficacy and safety of prasugrel in ACS patients...

..The aim of this study was to define, based on the published information, if carotid artery stenting is beneficial in this setting...

..To evaluate the ability of quantitative perfusion cardiac magnetic resonance (CMR) to assess the hemodynamic significance of coronary artery disease (CAD) compared with well-established anatomic and physiologic techniques...

..Comprehensive LL analyses, including MaxLL and AvgLL, provides a better appraisal of the biological and clinical effectiveness of DES...

..The objective of our study was to investigate the correlation between angiography, intravascular ultrasound (IVUS), and fractional flow reserve (FFR) in patients with moderate stenoses in small (<2.8 mm) coronary arteries...

..Our goal is to report the first large multicenter data for percutaneous coronary intervention (PCI) of bifurcation disease with drug-eluting stents (DES) in the United States...

....

..The pathogenesis and therapeutic options for SVG disease is reviewed in this article...

..The aim of this study was to evaluate the diagnostic accuracy of myocardial perfusion reserve (MPR) based on cMRI compared with SPECT...

..This article provides an overview of the current status of knowledge on cangrelor, focusing on its pharmacologic properties, clinical development and potential future applications...

..Thrombin receptor antagonists blocking protease-activated receptor-1 (PAR-1) on platelets represent a new class of oral antiplatelet agents for patients with atherothrombotic disease manifestations...

..This article provides an overview of the current status of knowledge on cangrelor, focusing on its pharmacologic properties and clinical development...

..Our objective was to evaluate accuracy of various cMR imaging parameters to detect significant CAD as compared with angiography or fractional flow reserve (FFR)...

..This article provides an overview of the current level of knowledge regarding elinogrel, focusing on its pharmacologic properties and preclinical and early-phase clinical development...

....

..This manuscript will review the more recent data concerning these interventions and their individual characteristics...

..The objective of this study was to describe the intraplaque variability of coronary atherosclerosis in humans...

..The purpose of this study is to evaluate the accuracy of semiautomated analysis of contrast enhanced magnetic resonance angiography (MRA) in patients who have undergone standard angiographic evaluation for peripheral vascular disease (PVD)...

..The aim of this study was to assess neointimal hyperplasia following sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) implantation in a patients with complex coronary disease...

..We studied the efficacy of intracoronary brachytherapy (ICB) after successful coronary stenting in diabetic patients with de novo lesions...

..IBT for treatment of DES failure was shown to be both safe and efficient and, therefore, until ISR exists, IBT still remains an important player in this growing and even more challenging setting...

....

....

..This suggests the need for individualized antithrombotic regimens to optimally inhibit platelet reactivity...

....

..The aim of this study was to assess whether body mass index (BMI) influenced platelet response to clopidogrel LD in patients undergoing CS...

..At the time of stent thrombosis, evaluation of platelet aggregation was performed, revealing a suboptimal response to aspirin. Pathophysiological insights of aspirin resistance and clinical implications are reviewed...

..In this article, we review the common drawbacks of DES and IBT and their prevention...

..These results emphasized the need for improvement in contemporary percutaneous coronary intervention practices and technologies...

..In this manuscript, principles of radiation therapy, results of clinical trials, current clinical practice, and future perspectives of intracoronary brachytherapy are summarized...

..In conclusion, rapid desensitization is safe and highly effective in patients with aspirin sensitivity and coronary artery disease who undergo coronary stent implantation, including those who receive drug-eluting stents...

..We investigated whether the prognostic assessment in PVD patients could be improved by preoperative measurements of C-reactive protein (CRP)...

..Outcomes after percutaneous coronary interventions in diabetic patients are shadowed by the increased rate of recurrence compared with nondiabetic patients...